Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 275-602-1 | CAS number: 71550-21-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Genetic toxicity in vitro
Description of key information
In an Ames test Salmonella typhimurium strains TA1535, TA1537, TA102, TA98 and TA100 were treated with Bayscript Gelb GGN using the Ames pre-incubation method (Prival Mitchell Modification for Azo Compounds) at up to eight dose levels, in triplicate, both with and without the addition of a hamster liver homogenate metabolizing system (30% liver S9 in modified co‑factors). The dose range for Experiment 1 was predetermined and was 1.5 to 5000 mg/plate. The experiment was repeated on a separate day using fresh cultures of the bacterial strains and fresh test item formulations. The dose range for Experiment 2 was amended, following the results of Experiment 1, and was 15 to 5000 µg/plate. Six test item concentrations were selected in Experiment 2 in order to achieve both four non-toxic dose levels and the potential toxic limit of the test item. Bayscript Gelb GGN was negative (non-mutagenic) under the conditions of this test.
Bayscript Gelb GGN did not induce gene mutations in an HPRT assay according to OECD guideline 476 in V79 cells of the Chinese hamster. Under the experimental conditions the test item did not induce gene mutations at the HPRT locus in V79 cells. Bayscript Gelb GGN was negative (non-mutagenic) in this HPRT assay.
In an OECD guideline 487 (In vitro Mammalian Cell Micronucleus Test) study, Bayscript Gelb GGN did not induce a statistically significant increase in the frequency of binucleate cells with micronuclei in either the absence or presence of a metabolizing system. The test item was therefore considered to be non-clastogenic and non-aneugenic to human lymphocytes in vitro.
Bayscript Gelb GGN is considered to be negative (non-mutagenic) in this in vitro micronucleus test.
Link to relevant study records
- Endpoint:
- in vitro gene mutation study in bacteria
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- Experimental start date: 29 March 2017 Experimental completion date: 23 June 2017
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 471 (Bacterial Reverse Mutation Assay)
- GLP compliance:
- yes (incl. QA statement)
- Type of assay:
- bacterial reverse mutation assay
- Specific details on test material used for the study:
- Physical state/Appearance: Amber coloured solid pieces
Expiry Date: 22 June 2018
Storage Conditions: Room temperature in the dark - Target gene:
- histidine locus
- Species / strain / cell type:
- S. typhimurium TA 1535, TA 1537, TA 98, TA 100 and TA 102
- Metabolic activation:
- with and without
- Metabolic activation system:
- hamster liver S9
- Test concentrations with justification for top dose:
- Experiment 1: The maximum concentration was 5000 µg/plate (the maximum recommended dose level). Eight concentrations of the test item were tested: 1.5, 5, 15, 50, 150, 500, 1500 and 5000 µg/plate.
Experiment 2: The dose range used for Experiment 2 was determined by the results of Experiment 1 and was 15, 50, 150, 500, 1500 and 5000 µg/plate. - Vehicle / solvent:
- The test item was fully soluble in sterile distilled water at 50 mg/mL in solubility checks performed in house. Sterile distilled water was therefore selected as the vehicle. The homogeneity and stability was previously confirmed for the test item in sterile distilled water formulations (within Envigo study no. LR73TX).
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- Remarks:
- distilled water
- True negative controls:
- no
- Positive controls:
- yes
- Remarks:
- 3 µg/plate for TA100, 5 µg/plate for TA1535
- Positive control substance:
- N-ethyl-N-nitro-N-nitrosoguanidine
- Remarks:
- Absence of S9-mix
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- Remarks:
- distilled water
- True negative controls:
- no
- Positive controls:
- yes
- Remarks:
- 80 µg/plate for TA1537
- Positive control substance:
- 9-aminoacridine
- Remarks:
- Absence of S9-mix
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- Remarks:
- distilled water
- True negative controls:
- no
- Positive controls:
- yes
- Remarks:
- 0.2 µg/plate for TA98
- Positive control substance:
- other: 4-Nitroquinoline-1-oxide
- Remarks:
- Absence of S9-mix
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- Remarks:
- distilled water
- True negative controls:
- no
- Positive controls:
- yes
- Remarks:
- 0.5 µg/plate for TA102
- Positive control substance:
- mitomycin C
- Remarks:
- Absence of S9-mix
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- Remarks:
- distilled water
- True negative controls:
- no
- Positive controls:
- yes
- Remarks:
- 1 µg/plate for TA100, 2 µg/plate for TA1535 and TA1537
- Positive control substance:
- other: 2-Aminoanthracene
- Remarks:
- Presence of S9-mix
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- Remarks:
- distilled water
- True negative controls:
- no
- Positive controls:
- yes
- Remarks:
- 5 µg/plate for TA98
- Positive control substance:
- benzo(a)pyrene
- Remarks:
- Presence of S9-mix
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- Remarks:
- distilled water
- True negative controls:
- no
- Positive controls:
- yes
- Remarks:
- 10 µg/plate for TA102
- Positive control substance:
- other: 1, 8-Dihydroxyanthraquinone
- Remarks:
- Presence of S9-mix
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- Remarks:
- distilled water
- True negative controls:
- no
- Positive controls:
- yes
- Remarks:
- 50 µg/plate for TA100 and TA98
- Positive control substance:
- congo red
- Remarks:
- Presence of uninduced S9-mix
- Details on test system and experimental conditions:
- Experimental Design and Study Conduct
Test Item Preparation and Analysis
The test item was fully soluble in sterile distilled water at 50 mg/mL in solubility checks performed in house. Sterile distilled water was therefore selected as the vehicle. The homogeneity and stability was previously confirmed for the test item in sterile distilled water formulations (within Envigo study no. LR73TX).
The test item was accurately weighed and approximate half-log dilutions prepared in sterile distilled water by mixing on a vortex mixer and sonication for 20 minutes at 40 °C on the day of each experiment. Formulated concentrations were adjusted to allow for the stated impurity content (10.4%) of the test item. All formulations were used within four hours of preparation. Analysis was carried out in Experiment 1 to determine the concentration of the maximum test item formulation (50 mg/mL). Details of the analytical determinations are presented in Appendix 2 of the report.
Test for Mutagenicity: Experiment 1 – Pre-Incubation Method
The Prival-Mitchell modification to the standard Ames Test is necessary for the testing of azo dyes which can contain mutagenic aromatic amines which are not readily detected using the standard method (Prival and Mitchell (1982)). The modification differs in five key areas from the standard plate incorporation Ames Test:
• Uninduced hamster liver S9 rather than induced rat liver S9.
• 0.15 mL of S9 rather than the maximum of 0.05 mL of S9 in the standard Ames Test.
• The use of flavin mononucleotide (FMN), nicotinamide adenine dinucleotide (NADH), four times the standard amount of glucose-6-phosphate, and the inclusion of exogenous glucose 6 phosphate dehydrogenase in the co-factor mix.
• A 30 minute pre-incubation prior to the addition of the molten top agar.
• Vogel-Bonner plates containing 0.5% glucose instead of the standard 2% glucose.
Only the test item concentrations, vehicle and the positive control, Congo Red, were dosed using the Prival Mitchell modification.
Without Metabolic Activation
Measured aliquots (0.1 mL) of one of the bacterial cultures were dispensed into sets of test tubes followed by 0.5 mL of phosphate buffer and 0.1 mL of the test item formulation or vehicle. Each mixture was shaken gently at 37 ± 3 ºC for 30 ± 3 minutes. Then, 2 mL of molten, trace amino-acid supplemented, top agar was added to each tube. The mixture was vortexed and poured onto Vogel-Bonner minimal agar plates containing 0.5% glucose. Each concentration of the test item, appropriate positive control, and each bacterial strain, was assayed using triplicate plates.
With Metabolic Activation
The procedure was the same as described previously except that following the addition of the test item formulation and bacterial culture, 0.5 mL of hamster S9 mix was added to the molten trace amino-acid supplemented media instead of phosphate buffer. In addition, 0.1 mL of TA98 or TA100, 0.5 mL of uninduced hamster liver S9 and 0.1 mL of Congo Red at 50 µg/plate was dispensed into dosing tubes, incubated and overlaid onto 0.5% glucose Vogel Bonner plates as previously described.
The standard Ames positive controls were dosed using the pre-incubation method (previously described) where 0.1 mL of bacterial culture was mixed with 0.5 mL of rat liver S9-mix (phenobarbitone/B-naphthoflavone) or phosphate buffer and 2 mL of amino-acid supplemented top agar before overlaying onto 2% glucose Vogel-Bonner agar plates.
The negative (untreated) controls were dosed using the plate incorporation method where 0.1 mL of bacterial culture was mixed with 2 mL of amino-acid supplemented top agar before overlaying onto 2% glucose Vogel-Bonner agar plates.
Incubation and Scoring
All of the plates were incubated at 37 ± 3 ºC for approximately 48 hours and scored for the presence of revertant colonies using an automated colony counting system. The plates were viewed microscopically for evidence of thinning (toxicity). Several manual counts were required due to revertant colonies spreading slightly, thus distorting the actual plate count.
Test for Mutagenicity: Experiment 2 – Pre-Incubation Method
Experiment 2 was performed using the pre-incubation method in the presence and absence of metabolic activation.
Without Metabolic Activation
Testing was performed as described above
With Metabolic Activation
Testing was performed as described above
Incubation and Scoring
All of the plates were incubated at 37 ± 3 ºC for approximately 48 hours and scored for the presence of revertant colonies using an automated colony counting system. The plates were viewed microscopically for evidence of thinning (toxicity). Several manual counts were required due to revertant colonies spreading slightly, thus distorting the actual plate count. - Evaluation criteria:
- There are several criteria for determining a positive result. Any, one, or all of the following can be used to determine the overall result of the study:
1. A dose-related increase in mutant frequency over the dose range tested (De Serres and Shelby, 1979).
2. A reproducible increase at one or more concentrations.
3. Biological relevance against in-house historical control ranges.
4. Statistical analysis of data as determined by UKEMS (Mahon et al., 1989).
5. Fold increase greater than two times the concurrent solvent control for any tester strain (especially if accompanied by an out of historical range response (Cariello and Piegorsch, 1996)).
A test item will be considered non-mutagenic (negative) in the test system if the above criteria are not met.
Although most experiments will give clear positive or negative results, in some instances the data generated will prohibit making a definite judgment about test item activity. Results of this type will be reported as equivocal. - Statistics:
- Statistical significance was confirmed by using Dunnetts Regression Analysis (* = p < 0.05) for those values that indicate statistically significant increases in the frequency of revertant colonies compared to the concurrent solvent control.
- Species / strain:
- S. typhimurium TA 1535
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Species / strain:
- S. typhimurium TA 1537
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Species / strain:
- S. typhimurium TA 98
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Species / strain:
- S. typhimurium TA 100
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Species / strain:
- S. typhimurium TA 102
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Additional information on results:
- Prior to use, the master strains were checked for characteristics, viability and spontaneous reversion rate (all were found to be satisfactory). The amino acid supplemented top agar and the S9-mix used in both experiments was shown to be sterile. The test item formulation was also shown to be sterile. These data are not given in the report.
Results for the negative controls (spontaneous mutation rates) were considered to be acceptable. These data are for concurrent untreated control plates performed on the same day as the Mutation Test.
The vehicle (sterile distilled water) control plates gave counts of revertant colonies within the normal range. All of the positive control chemicals used in the test induced marked increases in the frequency of revertant colonies, both with and without metabolic activation. Thus, the sensitivity of the assay and the efficacy of the induced rat liver and the uninduced hamster liver S9-mixes were validated.
The maximum dose level of the test item in the first experiment was selected as the maximum recommended dose level of 5000 µg/plate. There was no visible reduction in the growth of the bacterial background lawn at any dose level, either in the presence or absence of metabolic activation (S9-mix), in the first mutation test and consequently the same maximum dose level was used in the second mutation test. Similarly, there was no visible reduction in the growth of the bacterial background lawn at any dose level, either in the presence or absence of metabolic activation (S9-mix), in the second mutation test. A yellow test item induced colouration was noted from 15 µg/plate, becoming orange at 5000 g/plate, this observation did not prevent the scoring of revertant colonies.
There were no increases in the frequency of revertant colonies recorded for any of the bacterial strains, with any dose of the test item, either with or without metabolic activation (S9-mix) in Experiment 1. Similarly, no increases in the frequency of revertant colonies were recorded for any of the bacterial strains, with any dose of the test item, either with or without metabolic activation (S9-mix) in Experiment 2. - Conclusions:
- Bayscript Gelb GGN was considered to be non-mutagenic under the conditions of this test.
- Executive summary:
Introduction
The test method was designed to be compatible with the guidelines for bacterial mutagenicity testing published by the major Japanese Regulatory Authorities including METI, MHLW and MAFF, the OECD Guidelines for Testing of Chemicals No. 471 "Bacterial Reverse Mutation Test", Method B13/14 of Commission Regulation (EC) number 440/2008 of 30 May 2008 and the USA, EPA OCSPP harmonized guideline - Bacterial Reverse Mutation Test.
Methods
Salmonella typhimuriumstrains TA1535, TA1537, TA102, TA98 and TA100 were treated withBayscript Gelb GGNusing the Ames pre-incubation method (Prival Mitchell Modification for Azo Compounds)at up to eight dose levels, in triplicate, both with and without the addition of a hamster liver homogenate metabolizing system (30% liver S9 in modified co‑factors). The dose range for Experiment 1 was predetermined and was 1.5 to 5000 mg/plate. The experiment was repeated on a separate day using fresh cultures of the bacterial strains and fresh test item formulations. The dose range for Experiment 2 was amended, following the results of Experiment 1, and was 15 to 5000 µg/plate. Six test item concentrations were selected in Experiment 2 in order to achieve both four non‑toxic dose levels and the potential toxic limit of the test item.
Formulation analysis was carried out in Experiment 1 to determine the concentration of the test item concentration (maximum dose).
Results
The vehicle (sterile distilled water) control plates gave counts of revertant colonies within the normal range. All of the positive control chemicals used in the test induced marked increases in the frequency of revertant colonies, both with and without metabolic activation. Thus, the sensitivity of the assay and the efficacy of the induced rat liver and the uninduced hamster liver S9-mixes were validated.
The maximum dose level of the test item in the first experiment was selected as the maximum recommended dose level of 5000 µg/plate. There was no visible reduction in the growth of the bacterial background lawn at any dose level, either in the presence or absence of metabolic activation (S9-mix), in the first mutation test and consequently the same maximum dose level was used in the second mutation test. Similarly, there was no visible reduction in the growth of the bacterial background lawn at any dose level, either in the presence or absence of metabolic activation (S9-mix), in the second mutation test. A yellow test item induced colouration was noted from 15 µg/plate, becoming orange at 5000mg/plate, this observation did not prevent the scoring of revertant colonies.
There were no increases in the frequency of revertant colonies recorded for any of the bacterial strains, with any dose of the test item, either with or without metabolic activation (S9-mix) in Experiment 1. Similarly, no increases in the frequency of revertant colonies were recorded for any of the bacterial strains, with any dose of the test item, either with or without metabolic activation (S9-mix) in Experiment 2.
Conclusion
Bayscript Gelb GGNwas considered to be non-mutagenic under the conditions of this test.
- Endpoint:
- in vitro gene mutation study in mammalian cells
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- Experimental start date: 16 November 2017. Experimental completion date: 18 December 2017
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 476 (In Vitro Mammalian Cell Gene Mutation Test)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Type of assay:
- other: in vitro mammalian forward mutation assay
- Specific details on test material used for the study:
- Appearance Solid, crystalline, red-brown
Storage Conditions: At room temperature
Stability in Solvent: Stable in water at concentrations of 1 to 200 mg/mL for one day at 15 to 25 °C, and for 15 days at 2 to 8 °C: based on Envigo Study no. LR73TX.
Dose calculation was adjusted to purity. - Target gene:
- HPRT (hypoxanthine-guanine phosphoribosyl transferase) gene locus
- Species / strain / cell type:
- Chinese hamster lung fibroblasts (V79)
- Details on mammalian cell type (if applicable):
- The V79 cell line has been used successfully in in vitro experiments for many years. Especially the high proliferation rate (doubling time 12 - 16 h in stock cultures) and a good cloning efficiency of untreated cells (as a rule more than 50%) both necessary for the appropriate performance of the study, recommend the use of this cell line. The cells have a stable karyotype with a modal chromosome number of 22.
Cell Cultures
Large stocks of the V79 cell line (supplied by Laboratory for Mutagenicity Testing; Technical University, 64287 Darmstadt, Germany) are stored in liquid nitrogen in the cell bank of Envigo CRS GmbH allowing the repeated use of the same cell culture batch in experiments. Before freezing, the level of spontaneous mutants may be reduced by treatment with HAT-medium. Each master cell stock is screened for mycoplasm contamination and checked for karyotype stability and spontaneous mutant frequency. Consequently, the parameters of the experiments remain similar because of the reproducible characteristics of the cells.
Thawed stock cultures were propagated at 37 °C in 75 cm2 plastic flasks. About 2-3 x 10^6 cells were seeded into each flask with 15 mL of MEM (minimal essential medium) containing Hank’s salts supplemented with 10% foetal bovine serum (FBS), neomycin (5 µg/mL) and amphotericin B (1%). The cells were sub-cultured once or twice weekly.
All incubations were done at 37°C with 1.5% carbon dioxide (CO2) in humidified air.
Culture Medium
For seeding of the cell cultures the complete culture medium was MEM (minimal essential medium) containing Hank’s salts, neomycin (5 µg/mL), 10% FBS, and amphotericin B (1 %). During treatment no FBS was added to the medium. For the selection of mutant cells the complete medium was supplemented with 11 µg/mL 6-thioguanine. All cultures were incubated at 37 °C in a humidified atmosphere with 1.5 % CO2 (98.5 % air). - Metabolic activation:
- with and without
- Metabolic activation system:
- Phenobarbital/β-naphthoflavone induced rat liver S9
- Test concentrations with justification for top dose:
- Pre-Test on Toxicity
Test item concentrations between 17.4 µg/mL and 2232 µg/mL were used. The highest concentration was chosen with respect to the OECD guideline 476 regarding the purity of the test item (89.6%).
The test medium was checked for precipitation or phase separation at the end of each treatment period (4 hours) before the test item was removed. No precipitation or phase separation was observed up to the highest concentration with and without metabolic activation.
In the pre-experiment no relevant toxic effects were observed after 4 hours in the presence and absence of metabolic activation.
Main Experiment
without S9 mix:69.8; 139.5; 279.0; and 558.0 µg/mL
with S9 mix: 69.8; 139.5; 279.0; and 558.0 µg/mL
The concentrations used in the main experiment were selected based on precipitation observed in the pre-experiment. The individual concentrations were spaced by a factor of 2. - Vehicle / solvent:
- The test item was dissolved in deionised water. The final concentration of deionised water in the culture medium was 10 %. The solvent was chosen to its solubility properties and its relative non-toxicity to the cell cultures.
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- Remarks:
- Deionised water
- True negative controls:
- no
- Positive controls:
- yes
- Remarks:
- 300 µg/mL = 2.4 mM
- Positive control substance:
- ethylmethanesulphonate
- Remarks:
- without metabolic activation
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- Remarks:
- Deionised water
- True negative controls:
- no
- Positive controls:
- yes
- Remarks:
- 2.3 µg/mL = 8.9 µM
- Positive control substance:
- 7,12-dimethylbenzanthracene
- Remarks:
- with metabolic activation
- Details on test system and experimental conditions:
- Pre-Test on Toxicity
A pre-test was performed in order to determine the toxicity of the test item. In addition the pH and osmolarity were measured. The general culturing and experimental conditions in this pre-test were the same as described below for the mutagenicity experiment.
In this pre-test approximately 1.5 million cells were seeded in 25 cm² flasks 24 hours prior to treatment. After approximately 24 hours the test item was added and the treatment proceeds for 4 hours (duplicate cultures per concentration level). Immediately after treatment the test item was removed by rinsing with PBS. Subsequently, the cells were trypsinized and suspended in complete culture medium. After an appropriate dilution the cell density was determined with a cell counter. Toxicity of the test item is evident as a reduction of the cell density compared to a corresponding solvent control. A cell density of approximately 1.5 million cells in 25 cm² flasks is about the same as approximately 10 million cells seeded in 175 cm² bottles 24 hours prior to treatment with the main experiment.
Experimental Performance
Seeding
Two to four days after sub-cultivation stock cultures were trypsinized at 37 °C for approximately 5 to 10 minutes. Then the enzymatic digestion was stopped by adding complete culture medium with 10% FBS and a single cell suspension was prepared. The trypsin concentration for all sub-culturing steps was 0.2% in saline.
Prior to the trypsin treatment the cells were rinsed with PBS. Approximately 0.7 to 1.2 x 10^7 were seeded in plastic flasks. The cells were grown for 24 hours prior to treatment.
Treatment
After 24 hours the medium was replaced with serum-free medium containing the test item, either without S9 mix or with 50 µL/mL S9 mix. Concurrent solvent and positive controls were treated in parallel. 4 hours after treatment, this medium was replaced with complete medium following two washing steps with PBS.
Immediately after the end of treatment the cells were trypsinised as described above and sub-cultivated. At least 2.0 x10^6 cells per experimental point (concentration series plus controls) were subcultured in 175 cm² flasks containing 30 mL medium.
Two additional 25 cm² flasks were seeded per experimental point with approx. 500 cells each to determine the relative survival (cloning efficiency I) as measure of test item induced cytotoxicity. The cultures were incubated at 37 °C in a humidified atmosphere with 1.5 % CO2.
The colonies used to determine the cloning efficiency I were fixed and stained 6 to 8 days after treatment as described below.
Three or four days after first sub-cultivation approximately 2.0 x10^6 cells per experimental point were sub-cultivated in 175 cm² flasks containing 30 mL medium.
Following the expression time of 7 days five 75 cm² cell culture flasks were seeded with about 4 to 5 x 10^5 cells each in medium containing 6-TG. Two additional 25 cm² flasks were seeded with approx. 500 cells each in non-selective medium to determine the viability (cloning efficiency II).
The cultures were incubated at 37 °C in a humidified atmosphere with 1.5% CO2 for about 8 days. The colonies were stained with 10% methylene blue in 0.01% KOH solution.
The stained colonies with more than 50 cells were counted. In doubt the colony size was checked with a preparation microscope. - Evaluation criteria:
- Evaluation of Results
A test item is classified as clearly mutagenic if, in any of the experimental conditions examined, all of the following criteria are met:
a) at least one of the test concentrations exhibits a statistically significant increase compared with the concurrent negative control,
b) the increase is dose-related when evaluated with an appropriate trend test,
c) any of the results are outside the distribution of the historical negative control data (e.g. Poisson-based 95% control limits).
A test item is classified as clearly non-mutagenic if, in all experimental conditions examined, all of the following criteria are met:
a) none of the test concentrations exhibits a statistically significant increase compared with the concurrent negative control,
b) there is no concentration-related increase when evaluated with an appropriate trend test,
c) all results are inside the distribution of the historical negative control data (based 95% control limits).
In cases when the response is neither clearly negative nor clearly positive as described above, or in order to judge the biological relevance of a result, the data should be evaluated by expert judgement or further investigations. - Statistics:
- A linear regression (least squares, calculated using a validated excel spreadsheet) was performed to assess a possible dose dependent increase of mutant frequencies. The numbers of mutant colonies generated with the test item were compared to the solvent control groups. A trend is judged as significant whenever the p-value (probability value) is below 0.05.
- Species / strain:
- Chinese hamster lung fibroblasts (V79)
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Additional information on results:
- The test item Bayscript Gelb GGN was assessed for its potential to induce gene mutations at the HPRT locus using V79 cells of the Chinese hamster. The treatment period was 4 hours with and without metabolic activation.
The main experiment was evaluated at the following concentrations:
without S9 mix: 69.8; 139.5; 279.0; and 558.0 µg/mL
with S9 mix: 69.8; 139.5; 279.0; and 558.0 µg/mL
Precipitation visible at the end of treatment was noted at 558.0 µg/mL with and without metabolic activation.
No relevant cytotoxic effect indicated by an adjusted cloning efficiency I below 50% was observed neither in absence nor presence of metabolic activation.
No biologically relevant increase in mutant colony numbers was observed in the main experiment up to the maximum concentrations scored for gene mutations.
The mean mutant frequency obtained in the solvent controls was 21.5 and 22.0 mutants per 10^6 cells. The values were well within the 95% confidence interval of our laboratory’s historical negative control data and, thus, fulfilled the requirements of the current OECD Guideline 476. The range of the mean mutant frequencies of the groups treated with the test item was from 10.1 up to 25.5 mutants per 10^6 cells.
The linear regression analysis showed no significant dose dependend trend of the mutation frequency regarding the mean p-values with and without metabolic actvation. The significant trend calculated in the second culture with metabolic activation is judged as irrelevant, since it actually is reciprocal, going down versus increasing concentrations.
EMS (300 µg/mL) and DMBA (2.3 µg/mL) were used as positive controls and showed a distinct increase in induced mutant colonies. - Conclusions:
- In conclusion it can be stated that under the experimental conditions reported the test item did not induce gene mutations at the HPRT locus in V79 cells.
Therefore, Bayscript Gelb GGN is considered to be non-mutagenic in this HPRT assay. - Executive summary:
The study was performed to investigate the potential of Bayscript Gelb GGN to induce gene mutations at the HPRT locus in V79 cells of the Chinese hamster.
The main experiment was performed with a treatment period of 4 hours with and without metabolic activation.
The maximum test item concentration of the pre-experiment (2232 µg/mL) was chosen with respect to the OECD guideline 476 regarding the purity of the test item.
No relevant increase in mutant colony numbers/106cells was observed in the main experiments up to the maximum concentration.
Appropriate reference mutagens, used as positive controls, induced a distinct increase in mutant colonies and thus, showed the sensitivity of the test system and the activity of the metabolic activation system.
Conclusion
In conclusion it can be stated that under the experimental conditions reported the test item did not induce gene mutations at the HPRT locus in V79 cells.
Therefore, Bayscript Gelb GGN is considered to be non-mutagenic in this HPRT assay.
- Endpoint:
- in vitro cytogenicity / micronucleus study
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- Experimental start date: 09 May 2017 Experimental completion date: 12 July 2017
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 487 (In vitro Mammalian Cell Micronucleus Test)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Type of assay:
- in vitro mammalian cell micronucleus test
- Specific details on test material used for the study:
- Identification: Bayscript Gelb GGN
Alternative Names: Bayscript Yellow GGN
Benzenesulfonic acid, 3,3’-(carbonylbis(imino(3-methoxy-4,1-phenylene)-2,1-diazenediyl))bis-, compd. with 2,2’-iminobis(ethanol) (1:2)
Physical state/Appearance: Amber coloured solid pieces
Total Correction Factor: 1.12
Expiry Date: 22 June 2018
Storage Conditions: Room temperature in the dark
Formulated concentrations were adjusted to allow for the stated water/impurity content (10.4%) of the test item. - Target gene:
- not applicable
- Species / strain / cell type:
- primary culture, other: whole blood
- Details on mammalian cell type (if applicable):
- Cells
For each experiment, sufficient whole blood was drawn from the peripheral circulation of a non smoking volunteer (18-35) who had been previously screened for suitability. The volunteer had not knowingly been exposed to high levels of radiation or hazardous chemicals and had not knowingly recently suffered from a viral infection. Based on over 20 years in house data for cell cycle times for lymphocytes using BrdU (bromodeoxyuridine) incorporation to assess the number of first, second and third division metaphase cells to calculate the average generation time (AGT) for human lymphocytes it is considered to be approximately 16 hours. Therefore using this average the in-house exposure time for the experiments for 1.5 x AGT is 24 hours.
The details of the donors used are:
Preliminary Toxicity Test: male, aged 25 years
Main Experiment: male, aged 29 years
Cell Culture
Cells (whole blood cultures) were grown in Eagle's minimal essential medium with HEPES buffer (MEM), supplemented “in-house” with L-glutamine, penicillin/streptomycin, amphotericin B and 10% fetal bovine serum (FBS), at approximately 37 ºC with 5% CO2 in humidified air. The lymphocytes of fresh heparinized whole blood were stimulated to divide by the addition of phytohaemagglutinin (PHA). - Cytokinesis block (if used):
- cytochalasin B
- Metabolic activation:
- with and without
- Metabolic activation system:
- Phenobarbital/B-naphthoflavone induced rat liver S9
- Test concentrations with justification for top dose:
- Preliminary toxicity test:
All exposure groups: 0, 7.81, 15.63, 31.25, 62.5, 125, 250, 500, 1000 and 2000 µg/mL.
Main experiment:
4-hour exposure group (-S9): 0, 62.5, 125, 250, 500, 1000 and 2000 µg/mL
4-hour exposure group (+S9): 0, 62.5, 125, 250, 500, 1000 and 2000 µg/mL
24-hour exposure group (-S9): 0, 62.5, 125, 250, 500, 1000 and 2000 µg/mL - Vehicle / solvent:
- The test item was soluble in water at 20 mg/mL in solubility checks performed in house, therefore water was used as the vehicle
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- Remarks:
- sterile water
- True negative controls:
- no
- Positive controls:
- yes
- Remarks:
- 0.2 µg/mL for 4-hour exposure
- Positive control substance:
- mitomycin C
- Remarks:
- Absence of S9-mix
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- Remarks:
- sterile water
- True negative controls:
- no
- Positive controls:
- yes
- Remarks:
- 0.075 µg/mL for 24-hour continuous exposure
- Positive control substance:
- other: Demecolcine
- Remarks:
- Absence of S9-mix
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- Remarks:
- sterile water
- True negative controls:
- no
- Positive controls:
- yes
- Remarks:
- 5 µg/mL for 4-hour exposure
- Positive control substance:
- cyclophosphamide
- Remarks:
- Presence of S9-mix
- Details on test system and experimental conditions:
- Culture conditions
Duplicate lymphocyte cultures (A and B) were established for each dose level by mixing the following components, giving, when dispensed into sterile plastic flasks for each culture:
8.05-9.05 mL MEM, 10% (FBS)
0.1 mL Li-heparin
0.1 mL phytohaemagglutinin
0.75 mL heparinized whole blood
4-Hour Exposure With Metabolic Activation (S9)
After approximately 48 hours incubation at approximately 37 ºC, 5% CO2 in humidified air, the cultures were transferred to tubes and centrifuged. Approximately 9 mL of the culture medium was removed, reserved, and replaced with the required volume of MEM (including serum) and 1.0 mL of the appropriate solution of vehicle control or test item was added to each culture. For the positive control, 0.1 mL of the appropriate solution was added to the cultures. 1.0 mL of 20% S9-mix (i.e. 2% final concentration of S9 in standard co factors) was added to the cultures of the Preliminary Toxicity Test and the Main Experiment. All cultures were then returned to the incubator. The nominal total volume of each culture was 10 mL.
After 4 hours at approximately 37 ºC, the cultures were centrifuged, the treatment medium removed by suction and replaced with an 8 mL wash of MEM culture medium. After a further centrifugation the wash medium was removed by suction and replaced with the reserved original culture medium, supplemented with Cytochalasin B at a final concentration of 4.5 µg/mL, and then incubated for a further 24 hours.
4-Hour Exposure Without Metabolic Activation (S9)
After approximately 48 hours incubation at approximately 37 ºC with 5% CO2 in humidified air, the cultures were decanted into tubes and centrifuged. Approximately 9 mL of the culture medium was removed and reserved. The cells were then resuspended in the required volume of fresh MEM (including serum) and dosed with 1.0 mL of the appropriate vehicle control, test item solution or 0.1 mL of positive control solution. The nominal total volume for each culture was 10 mL.
After 4 hours at approximately 37 ºC, the cultures were centrifuged, the treatment medium was removed by suction and replaced with an 8 mL wash of MEM culture medium. After a further centrifugation the wash medium was removed by suction and replaced with the reserved original culture medium, supplemented with Cytochalasin B, at a final concentration of 4.5 µg/mL, and then incubated for a further 24 hours.
24-Hour Exposure Without Metabolic Activation (S9)
The exposure was continuous for 24 hours in the absence of metabolic activation. Therefore, when the cultures were established the culture volume was a nominal 9 mL. After approximately 48 hours incubation the cultures were removed from the incubator and dosed with 1.0 mL of vehicle control, test item dose solution or 0.1 mL of positive control solution. The nominal total volume of each culture was 10 mL. The cultures were then incubated for 24 hours, at approximately 37 ºC with 5% CO2 in humidified air, the tubes and the cells washed in MEM before resuspension in fresh MEM with serum. At this point Cytochalasin B was added at a final concentration of 4.5 µg/mL, and then the cells were incubated for a further 24 hours.
The extended exposure detailed above does not follow the suggested cell treatment schedule in the Guideline. This is because it avoids any potential interaction between Cytochalasin B and the test item during exposure to the cells and any effect this may have on the activity or response. Additionally, as the stability or reactivity of the test item is unknown prior to the start of the study this modification of the schedule is considered more effective and reproducible due to the in-house observations on human lymphocytes and their particular growth characteristics in this study type and also the significant laboratory historical control data using the above format.
The preliminary toxicity test was performed using the exposure conditions as described for the Main Experiment but using single cultures only, whereas the Main Experiment used replicate cultures.
Preliminary Toxicity Test
Three exposure groups were used:
i) 4-hour exposure to the test item without S9-mix, followed by a 24 hour incubation period in treatment-free media, in the presence of Cytochalasin B, prior to cell harvest.
ii) 4-hour exposure to the test item with S9-mix (2%), followed by a 24 hour incubation period in treatment-free media, in the presence of Cytochalasin B, prior to cell harvest.
iii) 24-hour continuous exposure to the test item without S9-mix, followed by a 24 hour incubation period in treatment-free media, in the presence of Cytochalasin B, prior to cell harvest.
The dose range of test item used was 7.81 to 2000 µg/mL.
Parallel flasks, containing culture medium without whole blood, were established for the three exposure conditions so that test item precipitate observations could be made. Precipitate observations were recorded at the beginning and end of the exposure periods.
Using a qualitative microscopic evaluation of the microscope slide preparations from each treatment culture, appropriate dose levels were selected for the evaluation of the frequency of binucleate cells and to calculate the cytokinesis block proliferation index (CBPI). Coded slides were evaluated for the CBPI. The CBPI data were used to estimate test item toxicity and for selection of the dose levels for the experiments of the main test.
Main Experiment
Three exposure groups were used for Main Experiment:
i) 4-hour exposure to the test item without S9-mix, followed by a 24 hour incubation period in treatment-free media, in the presence of Cytochalasin B, prior to cell harvest.
ii) 4-hour exposure to the test item with S9-mix (2%), followed by a 24 hour incubation period in treatment-free media, in the presence of Cytochalasin B, prior to cell harvest.
iii) 24-hour continuous exposure to the test item without S9-mix, followed by a 24-hour incubation period in treatment-free media, in the presence of Cytochalasin B, prior to cell harvest.
The dose range of test item used for all three exposure conditions was 62.5, 125, 250, 500, 1000 and 2000 µg/mL.
A sample was taken from the maximum dose formulation (20 mg/ml) for dose formulation analysis.
Cell Harvest
At the end of the Cytochalasin B treatment period the cells were centrifuged, the culture medium was drawn off and discarded, and the cells resuspended in MEM. The cells were then treated with a mild hypotonic solution (0.0375M KCl) before being fixed with fresh methanol/glacial acetic acid (19:1 v/v). The fixative was changed at least three times and the cells stored at approximately 4 ºC prior to slide making.
Preparation of Microscope Slides
The lymphocytes were re-suspended in several mL of fresh fixative before centrifugation and re suspension in a small amount of fixative. Several drops of this suspension were dropped onto clean, wet microscope slides and left to air dry. Each slide was permanently labelled with the appropriate identification data.
Staining
When the slides were dry they were stained in 5% Giemsa for 5 minutes, rinsed, dried and a cover slip applied using mounting medium. - Evaluation criteria:
- Providing that all of the acceptability criteria are fulfilled, a test item is considered to be clearly negative if, in most/all of the experimental conditions examined:
1. None of the test concentrations exhibits a statistically significant increase compared with the concurrent negative control.
2. There is no dose-related increase.
3. The results in all evaluated dose groups should be within the range of the laboratory historical control data.
Providing that all of the acceptability criteria are fulfilled, a test item may be considered to be clearly positive, if in any of the experimental conditions examined, there is one or more of the following applicable:
1. At least one of the test concentrations exhibits a statistically significant increase compared with the concurrent negative control.
2. There is an increase which can be considered to be dose-related.
3. The results are substantially outside the range of the laboratory historical negative control data.
When all the criteria are met, the test item is considered able to induce chromosome breaks and/or gain or loss in this test system.
There is no requirement for verification of a clear positive or negative response.
In case the response is neither clearly negative nor clearly positive as described above or in order to assist in establishing the biological relevance of a result, the data should be evaluated by expert judgment and/or further investigations. The Study Director may make a judgment based on experience and the biological relevance of the data and any justification for acceptance of the data will be included in the report. Scoring additional cells (where appropriate) or performing a repeat experiment possibly using modified experimental conditions (e.g. concentration spacing, other metabolic activation conditions (i.e. S9 concentration or S9 origin)) could be useful. Any additional work to verify an equivocal response will incur extra charges. - Statistics:
- The frequency of binucleate cells with micronuclei was compared, where necessary, with the concurrent vehicle control value using the Chi-squared Test on observed numbers of cells with micronuclei. Other statistical analyses may be used if appropriate (Hoffman et al., 2003). A toxicologically significant response was recorded when the p value calculated from the statistical analysis of the frequency of binucleate cells with micronuclei was less than 0.05 and there was a dose-related increase in the frequency of binucleate cells with micronuclei which was reproducible.
- Species / strain:
- primary culture, other: whole blood
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Additional information on results:
- Preliminary Toxicity Test
The dose range for the Preliminary Toxicity Test was 7.81, 15.63, 31.25, 62.5, 125, 250, 500, 1000, and 2000 µg/mL. The maximum dose was the maximum recommended dose level.
No precipitate of the test item was observed in the parallel blood-free cultures at the end of the exposure, in any of the three exposure groups.
Microscopic assessment of the slides prepared from the exposed cultures showed that binucleate cells were present at up to 2000 µg/mL in the 4-hour exposure, both in the presence and absence of metabolic activation (S9) and in the 24-hour exposure group. The test item induced no evidence of toxicity in either of the 4(20)-hour exposure groups and demonstrated very modest toxicity in the 24-hour exposure group.
The maximum dose level selected for the Main Experiment was the maximum recommended dose level, 2000 µg/mL for all three exposure groups.
Micronucleus Test – Main Experiment
The qualitative assessment of the slides determined that the toxicity was similar to that seen in the Preliminary Toxicity Test and that there were binucleate cells suitable for scoring at the maximum dose level of test item, 2000 µg/mL in all three exposure groups.
The CBPI data confirm the qualitative observations in that no marked dose-related inhibition of CBPI was observed in either of the 4(20)-hour exposure groups. In the 24-hour exposure group, dose related toxicity was observed with 23%, 40% and 55% cytostasis at 500, 1000 and 2000 µg/mL, respectively.
The maximum dose level selected for analysis of binucleate cells was the maximum recommended dose level (2000 µg/mL).
The vehicle control cultures had frequencies of cells with micronuclei within the expected range. The positive control items induced statistically significant increases in the frequency of cells with micronuclei. Thus, the sensitivity of the assay and the efficacy of the S9-mix were validated.
The test item did not induce any statistically significant increases in the frequency of binucleate cells with micronuclei, either in the absence or presence of metabolic activation.
The formulation analysis demonstrated accurate formulation of the test item. - Conclusions:
- The test item, Bayscript Gelb GGN, did not induce a statistically significant increase in the frequency of binucleate cells with micronuclei in either the absence or presence of a metabolizing system. The test item was therefore considered to be non-clastogenic and non-aneugenic to human lymphocytes in vitro.
- Executive summary:
Introduction
This report describes the results of an in vitro study for the detection of the clastogenic and aneugenic potential of the test item on the nuclei of normal human lymphocytes.
Methods
Duplicate cultures of human lymphocytes, treated with the test item, were evaluated for micronuclei in binucleate cells three dose levels, together with vehicle and positive controls. Three exposure conditions in a single experiment were used for the study using a 4-hour exposure in the presence and absence of a standard metabolizing system (S9) at a 2% final concentration and a 24-hour exposure in the absence of metabolic activation. At the end of the exposure period, the cell cultures were washed and then incubated for a further 24 hours in the presence of Cytochalasin B.
The dose levels used in the Main Experiment were selected using data from the preliminary toxicity test where the results indicated that the maximum concentration should be the maximum recommended dose level. The dose levels selected for the Main Test were as follows:
Exposure Group
Final concentration of test itemBayscript Gelb GGN(µg/mL)
4-hour without S9
0, 62.5, 125, 250, 500, 1000, 2000
4-hour with S9 (2%)
0, 62.5, 125, 250, 500, 1000, 2000
24-hour without S9
0, 62.5, 125, 250, 500, 1000, 2000
Dose formulation analysis was performed on the top dose formulation (20 mg/mL) of the main test.
Results
All vehicle (sterile water) controls had frequencies of cells with micronuclei in the binucleate cells within the range expected for normal human lymphocytes.
The positive control items induced statistically significant increases in the frequency of cells with micronuclei. Thus, the sensitivity of the assay and the efficacy of the S9-mix were validated.
The test item did not induce any statistically significant increases in the frequency of cells with micronuclei, using a dose range that included a dose level that was the lowest precipitating dose level. The test item did not demonstrate any toxicity in the 4-hour exposure groups and only modest toxicity at the upper end of the dose range in the 24-hour exposure groups.
The dose formulation analysis demonstrated accurate formulation of the test item at 20 mg/mL.
Conclusion
The test item, Bayscript Gelb GGN was considered to be non-clastogenic and non-aneugenic to human lymphocytes in vitro.
Referenceopen allclose all
Spontaneous Mutation Rates (Concurrent Negative Controls)
Experiment 1
Number of revertants (mean number of colonies per plate) |
|||||||||
Base-pair substitution type |
Frameshift type |
||||||||
TA100 |
TA1535 |
TA102 |
TA98 |
TA1537 |
|||||
93 |
|
24 |
|
305 |
|
11 |
|
11 |
|
90 |
(96) |
34 |
(29) |
247 |
(262) |
12 |
(13) |
15 |
(11) |
104 |
|
30 |
|
234 |
|
17 |
|
8 |
|
Experiment 2
Number of revertants (mean number of colonies per plate) |
|||||||||
Base-pair substitution type |
Frameshift type |
||||||||
TA100 |
TA1535 |
TA102 |
TA98 |
TA1537 |
|||||
135 |
|
31 |
|
321 |
|
18 |
|
19 |
|
119 |
(126) |
23 |
(26) |
302 |
(321) |
11 |
(18) |
13 |
(15) |
123 |
|
25 |
|
339 |
|
24 |
|
13 |
|
Test Results: Experiment 1 – Without Metabolic Activation
Test Period |
From: 16 May 2017 |
To: 19 May 2017 |
||||||||||
S9-Mix (-) |
Dose Level Per Plate |
Number of revertants (mean) +/- SD |
||||||||||
Base-pair substitution strains |
Frameshift strains |
|||||||||||
TA100 |
TA1535 |
TA102 |
TA98 |
TA1537 |
||||||||
Solvent Control (Water) |
85 83 76 |
(81) 4.7# |
23 32 33 |
(29) 5.5 |
250 264 271 |
(262) 10.7 |
14 12 16 |
(14) 2.0 |
9 7 13 |
(10) 3.1 |
||
1.5 µg |
87 82 88 |
(86) 3.2 |
28 36 24 |
(29) 6.1 |
210 229 241 |
(227) 15.6 |
14 17 10 |
(14) 3.5 |
7 21 7 |
(12) 8.1 |
||
5 µg |
81 94 76 |
(84) 9.3 |
12 22 28 |
(21) 8.1 |
219 177 278 |
(225) 50.7 |
10 13 18 |
(14) 4.0 |
9 14 10 |
(11) 2.6 |
||
15 µg |
87 80 75 |
(81) 6.0 |
17 22 20 |
(20) 2.5 |
233 219 238 |
(230) 9.8 |
11 14 9 |
(11) 2.5 |
15 17 9 |
(14) 4.2 |
||
50 µg |
88 73 80 |
(80) 7.5 |
29 18 8 |
(18) 10.5 |
238 266 277 |
(260) 20.1 |
11 17 12 |
(13) 3.2 |
15 15 5 |
(12) 5.8 |
||
150 µg |
74 72 76 |
(74) 2.0 |
27 21 29 |
(26) 4.2 |
258 264 260 |
(261) 3.1 |
13 17 11 |
(14) 3.1 |
7 5 7 |
(6) 1.2 |
||
500 µg |
72 75 83 |
(77) 5.7 |
18 28 16 |
(21) 6.4 |
257 291 269 |
(272) 17.2 |
11 8 14 |
(11) 3.0 |
3 6 7 |
(5) 2.1 |
||
1500 µg |
90 77 80 |
(82) 6.8 |
24 19 18 |
(20) 3.2 |
271 236 274 |
(260) 21.1 |
14 9 9 |
(11) 2.9 |
7 5 11 |
(8) 3.1 |
||
5000 µg |
83 80 72 |
(78) 5.7 |
21 18 20 |
(20) 1.5 |
206 250 263 |
(240) 29.9 |
10 8 10 |
(9) 1.2 |
5 6 17 |
(9) 6.7 |
||
Positive controls S9-Mix (-) |
Name Dose Level No. of Revertants |
ENNG |
ENNG |
MMC |
4NQO |
9AA |
||||||
3 µg |
5 µg |
0.5 µg |
0.2 µg |
80 µg |
||||||||
1557 1719 1536 |
(1604) 100.1 |
1037 963 1198 |
(1066) 120.2 |
1919 1813 2066 |
(1933) 127.1 |
349 386 369 |
(368) 18.5 |
311 398 355 |
(355) 43.5 |
|||
ENNG N-ethyl-N'-nitro-N-nitrosoguanidine
4NQO 4-Nitroquinoline-1-oxide
9AA 9-Aminoacridine
MMC Mitomycin C
# Standard deviation
Test Results: Experiment 1 – With Metabolic Activation
Test Period |
From: 16 May 2017 |
To: 19 May 2017 |
||||||||||
S9-Mix (+) |
Dose Level Per Plate |
Number of revertants (mean) +/- SD |
||||||||||
Base-pair substitution strains |
Frameshift strains |
|||||||||||
TA100 |
TA1535 |
TA102 |
TA98 |
TA1537 |
||||||||
Solvent Control (Water) |
118 117 104 |
(113) 7.8# |
29 30 21 |
(27) 4.9 |
359 257 320 |
(312) 51.5 |
40 28 32 |
(33) 6.1 |
21 6 5 |
(11) 9.0 |
||
1.5 µg |
112 95 125 |
(111) 15.0 |
25 19 21 |
(22) 3.1 |
247 277 319 |
(281) 36.2 |
21 32 22 |
(25) 6.1 |
10 5 7 |
(7) 2.5 |
||
5 µg |
111 100 94 |
(102) 8.6 |
21 21 20 |
(21) 0.6 |
291 263 262 |
(272) 16.5 |
24 24 13 |
(20) 6.4 |
5 3 7 |
(5) 2.0 |
||
15 µg |
99 93 115 |
(102) 11.4 |
17 27 12 |
(19) 7.6 |
349 218 249 |
(272) 68.5 |
12 31 43 |
(29) 15.6 |
11 12 9 |
(11) 1.5 |
||
50 µg |
102 103 111 |
(105) 4.9 |
16 22 14 |
(17) 4.2 |
320 305 328 |
(318) 11.7 |
27 40 9 |
(25) 15.6 |
6 11 13 |
(10) 3.6 |
||
150 µg |
84 103 92 |
(93) 9.5 |
26 22 23 |
(24) 2.1 |
299 299 357 |
(318) 33.5 |
27 43 26 |
(32) 9.5 |
14 12 6 |
(11) 4.2 |
||
500 µg |
91 92 111 |
(98) 11.3 |
24 30 26 |
(27) 3.1 |
283 318 309 |
(303) 18.2 |
20 33 26 |
(26) 6.5 |
6 4 16 |
(9) 6.4 |
||
1500 µg |
100 102 112 |
(105) 6.4 |
27 20 27 |
(25) 4.0 |
303 314 308 |
(308) 5.5 |
30 20 22 |
(24) 5.3 |
16 8 15 |
(13) 4.4 |
||
5000 µg |
80 99 85 |
(88) 9.8 |
24 23 18 |
(22) 3.2 |
254 283 302 |
(280) 24.2 |
14 27 28 |
(23) 7.8 |
12 11 11 |
(11) 0.6 |
||
Positive controls S9-Mix (+) |
Name Dose Level No. of Revertants |
2AA |
2AA |
DAN |
BP |
2AA |
||||||
1 µg |
2 µg |
10 µg |
5 µg |
2 µg |
||||||||
301 285 302 |
(296) 9.5 |
374 451 478 |
(434) 54.0 |
850 782 759 |
(797) 47.3 |
122 161 153 |
(145) 20.6 |
329 275 320 |
(308) 28.9 |
|||
Positive controls Hamster S9-Mix (+) |
Name |
CR |
|
CR |
|
|||||||
Dose Level |
50 µg |
50 µg |
||||||||||
No. of Revertants |
484 533 358 |
(458) 90.3 |
341 317 300 |
(319) 20.6 |
||||||||
BP Benzo(a)pyrene
2AA 2-Aminoanthracene
DAN 1,8-Dihydroxyanthraquinone
CR Congo Red
P Test item precipitate
S Sparse bacterial background lawn
T Toxic, no bacterial background lawn
V Very weak bacterial background lawn
# Standard deviation
Test Results: Experiment 2 – Without Metabolic Activation
Test Period |
From: 20 June 2017 |
To: 23 June 2017 |
||||||||||
S9-Mix (-) |
Dose Level Per Plate |
Number of revertants (mean) +/- SD |
||||||||||
Base-pair substitution strains |
Frameshift strains |
|||||||||||
TA100 |
TA1535 |
TA102 |
TA98 |
TA1537 |
||||||||
Solvent Control (Water) |
104 89 98 |
(97) 7.5# |
24 23 21 |
(23) 1.5 |
289 303 285 |
(292) 9.5 |
11 16 11 |
(13) 2.9 |
19 10 9 |
(13) 5.5 |
||
15 µg |
115 91 110 |
(105) 12.7 |
18 20 30 |
(23) 6.4 |
292 258 310 |
(287) 26.4 |
11 10 13 |
(11) 1.5 |
10 15 7 |
(11) 4.0 |
||
50 µg |
117 93 90 |
(100) 14.8 |
24 19 25 |
(23) 3.2 |
284 302 309 |
(298) 12.9 |
12 9 16 |
(12) 3.5 |
5 12 8 |
(8) 3.5 |
||
150 µg |
109 84 101 |
(98) 12.8 |
24 22 27 |
(24) 2.5 |
305 272 268 |
(282) 20.3 |
10 14 11 |
(12) 2.1 |
9 5 14 |
(9) 4.5 |
||
500 µg |
98 107 95 |
(100) 6.2 |
22 20 19 |
(20) 1.5 |
264 226 268 |
(253) 23.2 |
11 12 12 |
(12) 0.6 |
11 6 4 |
(7) 3.6 |
||
1500 µg |
96 113 111 |
(107) 9.3 |
14 20 20 |
(18) 3.5 |
251 237 315 |
(268) 41.6 |
9 11 10 |
(10) 1.0 |
7 5 7 |
(6) 1.2 |
||
5000 µg |
93 87 105 |
(95) 9.2 |
26 23 23 |
(24) 1.7 |
248 236 300 |
(261) 34.0 |
13 10 13 |
(12) 1.7 |
2 7 5 |
(5) 2.5 |
||
Positive controls S9-Mix (-) |
Name Dose Level No. of Revertants |
ENNG |
ENNG |
MMC |
4NQO |
9AA |
||||||
3 µg |
5 µg |
0.5 µg |
0.2 µg |
80 µg |
||||||||
761 663 680 |
(701) 52.4 |
799 755 744 |
(766) 29.1 |
2009 1633 1594 |
(1745) 229.2 |
263 253 299 |
(272) 24.2 |
381 267 303 |
(317) 58.3 |
|||
ENNG N-ethyl-N'-nitro-N-nitrosoguanidine
4NQO 4-Nitroquinoline-1-oxide
9AA 9-Aminoacridine
MMC Mitomycin C
# Standard deviation
Test Results: Experiment 2 – With Metabolic Activation
Test Period |
From: 16 May 2017 |
To: 19 May 2017 |
||||||||||
S9-Mix (+) |
Dose Level Per Plate |
Number of revertants (mean) +/- SD |
||||||||||
Base-pair substitution strains |
Frameshift strains |
|||||||||||
TA100 |
TA1535 |
TA102 |
TA98 |
TA1537 |
||||||||
Solvent Control (Water) |
124 112 117 |
(118) 6.0# |
29 21 23 |
(24) 4.2 |
349 308 314 |
(324) 22.1 |
18 21 22 |
(20) 2.1 |
20 18 20 |
(19) 1.2 |
||
15 µg |
113 127 109 |
(116) 9.5 |
26 23 17 |
(22) 4.6 |
332 316 340 |
(329) 12.2 |
23 26 17 |
(22) 4.6 |
27 18 17 |
(21) 5.5 |
||
50 µg |
110 114 102 |
(109) 6.1 |
27 25 22 |
(25) 2.5 |
294 343 348 |
(328) 29.8 |
24 14 16 |
(18) 5.3 |
16 32 23 |
(24) 8.0 |
||
150 µg |
129 117 123 |
(123) 6.0 |
27 23 25 |
(25) 2.0 |
340 334 353 |
(342) 9.7 |
17 14 22 |
(18) 4.0 |
24 18 18 |
(20) 3.5 |
||
500 µg |
107 120 112 |
(113) 6.6 |
20 28 21 |
(23) 4.4 |
328 304 305 |
(312) 13.6 |
18 21 16 |
(18) 2.5 |
26 10 15 |
(17) 8.2 |
||
1500 µg |
116 109 110 |
(112) 3.8 |
24 28 28 |
(27) 2.3 |
281 328 340 |
(316) 31.2 |
12 18 17 |
(16) 3.2 |
13 16 14 |
(14) 1.5 |
||
5000 µg |
115 110 116 |
(114) 3.2 |
25 29 18 |
(24) 5.6 |
344 236 270 |
(283) 55.2 |
16 18 18 |
(17) 1.2 |
19 13 9 |
(14) 5.0 |
||
Positive controls S9-Mix (+) |
Name Dose Level No. of Revertants |
2AA |
2AA |
DAN |
BP |
2AA |
||||||
1 µg |
2 µg |
10 µg |
5 µg |
2 µg |
||||||||
1035 908 927 |
(957) 68.5 |
207 213 241 |
(220) 18.1 |
718 627 693 |
(679) 47.0 |
133 124 109 |
(122) 12.1 |
119 173 322 |
(205) 105.1 |
|||
Positive controls Hamster S9-Mix (+) |
Name |
CR |
|
CR |
|
|||||||
Dose Level |
50 µg |
50 µg |
||||||||||
No. of Revertants |
816 778 792 |
(795) 19.2 |
220 223 232 |
(225) 6.2 |
||||||||
BP Benzo(a)pyrene
2AA 2-Aminoanthracene
DAN 1,8-Dihydroxyanthraquinone
CR Congo Red
# Standard deviation
The dose levels of the controls and the test item are given in the table below:
Exposure Group |
Final concentration of test itemBayscript Gelb GGN(µg/mL) |
4-hour without S9 |
0*, 62.5, 125, 250, 500*, 1000*, 2000*, MMC0.2* |
4-hour with S9 (2%) |
0*, 62.5, 125, 250, 500*, 1000*, 2000*, CP5* |
24-hour without S9 |
0*, 62.5, 125, 250, 500*, 1000*, 2000*,DC0.075* |
MMC = Mitomycin C
CP = Cyclophosphamide
DC = Demecolcine
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (negative)
Genetic toxicity in vivo
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Justification for classification or non-classification
Bayscript Gelb GGN was non-mutagenic (negative) in all in vitro tests. In a valid Ames test, in an HPRT assay according to OECD guideline 476 in V79 cells and an in vitro Mammalian Cell Micronucleus Test according to OECD guideline 487 Bayscript Gelb GGN was negative. According to CLP classification criteria (Regulation (EC) No 1272/2008) a classification is therefore not justified.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.